St. Jude Medical (NYSE: STJ) designs, manufactures, and distributes medical devices for heart-related and neurological conditions. The firm's Cardiac Rhythm Management segment makes pacemakers and implantable cardioverter defibrillators, to regulate heart rhythm. The Neuromodulation unit develops pacemaker-like implantable systems to treat chronic, intractable pain, and other nervous system disorders. The Cardiovascular division offers therapies and technologies for treating people with cardiovascular and peripheral vascular disease. The Atrial Fibrillation segment develops products to diagnose, treat, and seek a cure for atrial fibrillation. Boston Scientific (NYSE: BSX) is a major competitor.

The company pleased investors last week, when it reported Q2 EPS of 60 cents and revenues of $1.14 billion. Analysts had been expecting 55 cents and $1.06 billion. The CEO noted that revenue exceeded guidance in every business category. Management also guided Q3 EPS to 56-58 cents (53 cent consensus) and FY08 EPS to $2.28-$2.33 ($2.19 consensus).

Continue reading St. Jude Medical (STJ): Shares define bullish 'flag' pattern

St. Jude Medical (STJ): Shares define bullish 'flag' pattern originally appeared on BloggingStocks on Mon, 21 Jul 2008 12:00:00 EST. Please see our terms for use of feeds.

Being a particularly hard-working organ, the heart can be subject to bouts of irregular behavior. A world leader in the development and application of technologies designed to keep the heart running smoothly is headquartered in St. Paul, Minnesota.

St. Jude Medical Inc. (NYSE: STJ) designs, manufactures, and distributes medical devices for heart-related and neurological conditions. The firm's Cardiac Rhythm Management segment makes pacemakers and implantable cardioverter defibrillators, to regulate heart rhythm. The Neuromodulation unit develops pacemaker-like implantable systems to treat chronic, intractable pain, and other nervous system disorders. The Cardiovascular division offers therapies and technologies for treating people with cardiovascular and peripheral vascular disease. The Atrial Fibrillation segment develops products to diagnose, treat, and seek a cure for atrial fibrillation. Boston Scientific (NYSE: BSX) is a major competitor.

The company pleased investors last week, when it reported Q2 EPS of 45 cents and revenues of $947 million. Analysts had been expecting 43 cents and $909.8 million. Management also guided Q3 EPS to 44-45 cents (45 cent consensus) and FY07 EPS to $1.74-$1.78 ($1.75 consensus). Wachovia subsequently upgraded the shares to "outperform" and Jefferies termed the valuation "attractive." The stock popped into a bullish "pennant" consolidation pattern on the news. Prices frequently exit pennants moving in the same direction they were traveling when they entered them. In this case, that would be to the upside.

Altogether, brokers now recommend the issue with four "strong buys," nine "buys," nine "holds" and one "sell." Analysts see a 17% average annual growth rate, through the next five years. The STJ Sales Growth rate (13.69%), EPS Growth rate (18.42%), Operating Margin (21.46%), Net Profit Margin (15.65%), Return on Assets (11.12%), Return on Investment (13.68%) and Return on Equity (21.82%) compare favorably with industry, sector and S&P 500 averages.

The stock is one of those used to calculate the S&P 500 Index. Institutional investors hold about 80% of the outstanding shares. Over the past 52 weeks, STJ has traded between $32.33 and $45.39. A stop-loss of $39.50 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.

St. Jude Medical: Healing wounded hearts originally appeared on BloggingStocks on Mon, 23 Jul 2007 12:41:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY: Microsoft (MSFT) and Darden Restaurants (DRI) top today's list of upgrades.

• Credit Suisse upgraded Microsoft Corp. (NASDAQ:MSFT) to "Outperform" from Neutral, citing the company's strengthening market position in digital entertainment and potential revenue upside.
• JP Morgan upgraded Darden Restaurants, Inc. (NYSE:DRI) to Neutral from Underweight, reflecting lower commodity costs and solid performance in Olive Garden.

OTHER UPGRADES:

• Triad Hospitals, Inc. (NYSE:TRI) was upgraded from Reduce to Buy at UBS; the upgrade is based on the increased confidence Triad will implement strategic changes to increase shareholder value.
• Morgan Stanley expected a rebound in the ICD market and upgraded St. Jude Medical, Inc. (NYSE:STJ) to Overweight from Equal Weight.
• SafeNet Inc (NASDAQ:SFNT) was added to Stifel Nicolaus' Select List with a $31 target. SafeNet is said to be making progress with their stock option issues and they find the valuation to be attractive.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Analyst upgrades 11-20-06: Microsoft upgraded to Outperform originally appeared on BloggingStocks on Mon, 20 Nov 2006 11:11:00 EST. Please see our terms for use of feeds.